FRM
PNT

Fox Run Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Fox Run Management’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,744
Closed -$151K – 1034
2023
Q1 		$151K Buy
+20,744
New +$154K 0.05% 566

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's PNT Position: Q2 2023 in Review

Fox Run Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2023, closing a stake of 20,744 shares — an estimated $151K sold.

Fox Run Management first reported a position in PNT in Q1 2023 and held it in 1 quarter. The position peaked at $151K in Q1 2023. 130 funds tracked by Wall St. Rank hold PNT as of Q2 2023.

  • Fox Run Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Fox Run Management sold 20,744 POINT Biopharma Global Inc. Common Stock shares in Q2 2023, an estimated $151K.
  • Fox Run Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Fox Run Management's POINT Biopharma Global Inc. Common Stock position peaked at $151K in Q1 2023.
  • 130 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.